Antares Pharma Inc
NASDAQ:ATRS
Antares Pharma Inc
Operating Income
Antares Pharma Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Antares Pharma Inc
NASDAQ:ATRS
|
Operating Income
$27.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Antares Pharma Inc's Operating Income?
Operating Income
27.3m
USD
Based on the financial report for Dec 31, 2021, Antares Pharma Inc's Operating Income amounts to 27.3m USD.
What is Antares Pharma Inc's Operating Income growth rate?
Operating Income CAGR 1Y
101%
Over the last year, the Operating Income growth was 101%.